Abstract
CD8+ CTL are the predominant tumoricidal effector cells. We find, however, that MHC class I-deficient mice depleted of CD8+ T cells are able to mount an effective antitumor immunity after immunization with fused dendritic/tumor cells. Such immunity appears to be mediated by the generation of phenotypic and functional CD8+ CTL through CD4+ to CD8+ conversion, which we have demonstrated at the single cell level. CD4+ to CD8+ conversion depends on effective in vivo activation and is promoted by CD4+ T cell proliferation. The effectiveness of this process is shown by the generation of antitumor immunity through adoptive transfer of primed CD4 T cells to provide protection against tumor cell challenge and to eliminate established pulmonary metastases.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adoptive Transfer
-
Animals
-
Antigens, Neoplasm / immunology*
-
CD4-Positive T-Lymphocytes / cytology
-
CD4-Positive T-Lymphocytes / immunology*
-
CD4-Positive T-Lymphocytes / transplantation
-
CD8-Positive T-Lymphocytes / cytology
-
CD8-Positive T-Lymphocytes / immunology*
-
Cancer Vaccines
-
Cell Lineage / immunology*
-
Histocompatibility Antigens Class I / genetics
-
Histocompatibility Antigens Class I / immunology
-
Immunity
-
Immunization
-
Lymphocyte Activation / immunology
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
Mice, Transgenic
-
T-Lymphocytes, Cytotoxic / cytology
-
T-Lymphocytes, Cytotoxic / immunology*
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
Histocompatibility Antigens Class I